These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1448780

  • 21. ADP plays a key role in thrombogenesis in rats.
    Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL.
    Thromb Haemost; 1988 Apr 08; 59(2):225-30. PubMed ID: 3133809
    [Abstract] [Full Text] [Related]

  • 22. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
    Kotzé HF, Lamprecht S, Badenhorst PN, van Wyk V, Roodt JP, Alexander K.
    Thromb Haemost; 1993 Oct 18; 70(4):672-5. PubMed ID: 8115994
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
    Uematsu T, Nagashima S, Mizuno A, Hirano K, Nakashima M.
    J Clin Pharmacol; 1991 Sep 18; 31(9):815-22. PubMed ID: 1839540
    [Abstract] [Full Text] [Related]

  • 24. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y, Sugidachi A, Ogawa T, Jakubowski JA, Hashimoto M, Isobe T, Otsuguro K, Asai F.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):276-82. PubMed ID: 17996866
    [Abstract] [Full Text] [Related]

  • 25. Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder.
    Palea S, Toson G, Pietra C, Trist DG, Artibani W, Romano O, Corsi M.
    Br J Pharmacol; 1998 Jul 28; 124(5):865-72. PubMed ID: 9692770
    [Abstract] [Full Text] [Related]

  • 26. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear.
    Umemura K, Asai Y, Uematsu T, Nakashima M.
    Eur Arch Otorhinolaryngol; 1993 Jul 28; 250(6):342-4. PubMed ID: 8260145
    [Abstract] [Full Text] [Related]

  • 27. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E, Belogi L, Mezzadri CM.
    Arzneimittelforschung; 1996 Jan 28; 46(1):35-41. PubMed ID: 8821515
    [Abstract] [Full Text] [Related]

  • 28. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests.
    Krupiński K, Ferber H, Breddin HK, Bielawiec M.
    Acta Haematol Pol; 1994 Jan 28; 25(3):235-42. PubMed ID: 7992596
    [Abstract] [Full Text] [Related]

  • 29. Antithrombotic and antiplatelet activities of Korean red ginseng extract.
    Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, Im JH, Han XH, Kim TJ, Shin KS, Wee JJ, Yun YP.
    Basic Clin Pharmacol Toxicol; 2007 Mar 28; 100(3):170-5. PubMed ID: 17309520
    [Abstract] [Full Text] [Related]

  • 30. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN, Lorrain J, Lochot S, Delahaye M, Lalé A, Savi P, Lechaire I, Ferrari P, Bernat A, Schaeffer P, Janiak P, Duval N, Grosset A, Herbert JM, O'Connor SE.
    Thromb Haemost; 2001 Mar 28; 85(3):521-8. PubMed ID: 11307825
    [Abstract] [Full Text] [Related]

  • 31. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G, Casaní L, Badimon L.
    Thromb Haemost; 2007 Sep 28; 98(3):662-9. PubMed ID: 17849057
    [Abstract] [Full Text] [Related]

  • 32. Influence of age on the pharmacokinetics of vapiprost, a thromboxane A2 receptor antagonist, and platelet aggregation: comparison of pharmacokinetics by routine approach and population pharmacokinetics.
    Ohashi K, Aso R.
    Int J Clin Pharmacol Res; 2001 Sep 28; 21(2):85-94. PubMed ID: 11824652
    [Abstract] [Full Text] [Related]

  • 33. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C.
    J Pharmacol Exp Ther; 1994 Apr 28; 269(1):238-45. PubMed ID: 8169831
    [Abstract] [Full Text] [Related]

  • 34. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model.
    Takiguchi Y, Asai F, Wada K, Hayashi H, Nakashima M.
    Br J Pharmacol; 1995 Dec 28; 116(7):3056-60. PubMed ID: 8680743
    [Abstract] [Full Text] [Related]

  • 35. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec 28; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 36. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI, Fujishima K, Ikeda Y, Kondo K, Umemura K.
    J Cereb Blood Flow Metab; 2000 Jun 28; 20(6):988-97. PubMed ID: 10894182
    [Abstract] [Full Text] [Related]

  • 37. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K.
    Eur J Pharmacol; 2001 Apr 13; 417(3):217-22. PubMed ID: 11334853
    [Abstract] [Full Text] [Related]

  • 38. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C.
    Pharmacol Ther; 2005 Nov 13; 108(2):180-92. PubMed ID: 15955565
    [Abstract] [Full Text] [Related]

  • 39. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 13; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 40. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M, Golino P, Cirillo P, Pascucci I, Scognamiglio A, Ravera A, Esposito N, Battaglia C, Guarino A, Chiariello M.
    Cardiologia; 1996 Jan 13; 41(1):51-8. PubMed ID: 8697470
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.